Look into the landscape around TROP2 ADCs as frontrunners aim to expand and the next wave aims to develop safer drugs.

In an interview with Labiotech, Jacobs discussed the decisions behind Novavax’s transformation, the economics of its new ...

Discover five myopia companies racing to go beyond glasses, as myopia is set to affect half the world by 2050.

Delve into Labiotech's October oncology roundup and find out about the news that caught our attention this last month.

Delve into the field of B7-H3 ADCs, a new contender in SCLC cancer, as Hansoh Pharma and Medilink bring momentum with ...

Discover six companies advancing promising treatments for pulmonary hypertension beyond vasodilators, changing the standards of care.

Learn when TIDE-based Sanger sequencing can replace NGS for measuring on-target gene editing efficiency in regulated ...

Discover Novo's pipeline in 2026, as it recently set out a new plan to reach $23 billion in risk-adjusted pipeline sales by ...

Join leading experts to explore practical strategies for designing and delivering rare disease clinical trials in Europe.